Jonathan Zalevsky's most recent trade in Nektar Therapeutics was a trade of 10,712 Common Stock done at an average price of $0.7 . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.67 per share. | 19 May 2025 | 10,712 | 305,892 (0%) | 0% | 0.7 | 7,177 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Feb 2025 | 10,300 | 316,604 (0%) | 0% | 1.0 | 10,403 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.94 per share. | 19 Dec 2024 | 51,115 | 326,904 (0%) | 0% | 0.9 | 48,048 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 375,000 | 375,000 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 270,000 | 270,000 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 135,000 | 378,019 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.01 per share. | 19 Nov 2024 | 7,785 | 243,019 (0%) | 0% | 1.0 | 7,863 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 19 Aug 2024 | 6,866 | 250,804 (0%) | 0% | 1.3 | 8,788 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 1.75 per share. | 17 May 2024 | 7,355 | 257,670 (0%) | 0% | 1.7 | 12,871 | Common Stock |
| Nektar Therapeutics | Zalevsky Jonathan | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.68 per share. | 20 Feb 2024 | 9,014 | 265,025 (0%) | 0% | 0.7 | 6,130 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2023 | 250,000 | 250,000 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.78 per share. | 16 Aug 2023 | 9,703 | 283,685 (0%) | 0% | 0.8 | 7,568 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 0.72 per share. | 16 May 2023 | 9,791 | 293,388 (0%) | 0% | 0.7 | 7,050 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 3.00 per share. | 16 Feb 2023 | 10,484 | 303,179 (0%) | 0% | 3 | 31,452 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 4.65 per share. | 18 Aug 2022 | 73,716 | 327,123 (0%) | 0% | 4.6 | 342,779 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 270,000 | 270,000 | - | - | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 135,000 | 411,399 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 4.76 per share. | 15 Aug 2022 | 10,560 | 400,839 (0%) | 0% | 4.8 | 50,266 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 23,950 | 298,072 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 3.95 per share. | 15 May 2022 | 21,673 | 276,399 (0%) | 0% | 3.9 | 85,608 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 10.95 per share. | 16 Feb 2022 | 10,912 | 274,122 (0%) | 0% | 10.9 | 119,486 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 94,000 | 94,000 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2021 | 52,950 | 285,034 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 40,150 | 252,953 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 15 Nov 2021 | 20,869 | 232,084 (0%) | 0% | 13.2 | 274,636 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2021 | 71,550 | 71,550 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 13.83 per share. | 16 Aug 2021 | 7,662 | 212,803 (0%) | 0% | 13.8 | 105,965 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 18.30 per share. | 17 May 2021 | 31,111 | 235,065 (0%) | 0% | 18.3 | 569,331 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 22.37 per share. | 16 Feb 2021 | 24,141 | 266,176 (0%) | 0% | 22.4 | 540,034 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 71,500 | 71,500 | - | - | Stock Option | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2020 | 40,000 | 290,317 (0%) | 0% | 0 | Common Stock | |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 16.40 per share. | 23 Nov 2020 | 16,380 | 250,317 (0%) | 0% | 16.4 | 268,632 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 16.93 per share. | 16 Nov 2020 | 29,618 | 266,697 (0%) | 0% | 16.9 | 501,433 | Common Stock |
| Nektar Therapeutics | Jonathan Zalevsky | Chief R&D Officer | Sale of securities on an exchange or to another person at price $ 19.67 per share. | 17 Aug 2020 | 26,200 | 296,315 (0%) | 0% | 19.7 | 515,354 | Common Stock |